Disposition of oral lisuride in parkinson's disease | Zendy

Burns R Stanley | Zendy; Gopinathan G | Zendy; Hümpel Michael | Zendy; Dorow Rainer | Zendy; Calne Donald B | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Disposition of oral lisuride in parkinson's disease

Author(s) -

Burns R Stanley,

Gopinathan G,

Hümpel Michael,

Dorow Rainer,

Calne Donald B

Publication year - 1984

Publication title -

clinical pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.941

H-Index - 188

eISSN - 1532-6535

pISSN - 0009-9236

DOI - 10.1038/clpt.1984.76

Subject(s) - lisuride , pharmacokinetics , urine , pharmacology , chemistry , plasma concentration , absorption (acoustics) , radioimmunoassay , clinical pharmacology , disposition , drug , oral administration , oral dose , medicine , dopamine agonist , dopamine , psychology , dopaminergic , social psychology , physics , acoustics

The single and multiple oral dose plasma kinetics of lisuride were followed by a recently developed radioimmunoassay method in 11 patients with Parkinson's disease. A very wide range of plasma drug concentrations resulted from a single dose of 300 µg, as reflected in large interindividual differences in peak concentration (0.27 to 3.30 ng/ml) and AUC after the initial dose (43.1 to 617 ng · min/ml). Absorption was rapid, with a mean time to peak of 39 min. Only 0.05% of the dose was excreted unchanged in urine in 24 hr. There was a 110% increase in apparent oral clearance after 2 to 4 wk of treatment. Clinical Pharmacology and Therapeutics (1984) 35, 548–556; doi: 10.1038/clpt.1984.76

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research